Albemarle Corp (ALB) · Nov 4, 2026 · Earnings
Beat — Adjusted EPS $2.58 vs ~$2.52 consensus
Albemarle earnings beat Q3 expectations on higher lithium pricing, while a sharp capex cut improves cash flexibility ahead of a softer Q4.
Albemarle is in a lithium-cycle recovery and balance-sheet repair phase: lithium prices have rebounded from 2025 lows, while the company is emphasizing cost control, selective growth and debt reduction. Its prior outlook already assumed materially higher lithium prices and a recovery in earnings, so this quarter is mainly a test of execution against that improving backdrop.
The quarter beat the published benchmark, but only narrowly. Adjusted diluted EPS was $2.58 versus roughly $2.52-$2.53 consensus, while revenue was $1.553 billion versus about $1.52 billion expected. That makes this a genuine beat, but not a major reset of the recovery story. The filing says sales rose primarily because of higher prices in Energy Storage and Specialties, while adjusted EBITDA benefited from higher sales and cost improvements.
| Figure | Q3 2026 | Q3 2025 | Consensus / prior guide |
|---|---|---|---|
| Revenue (Financial Highlights) | $1,553.1M (+18.8%) | $1,307.8M | ~$1,520M |
| Adjusted diluted EPS (Financial Highlights) | $2.58 | $(0.19) | ~$2.52 |
| Adjusted EBITDA (Financial Highlights) | $645.5M (+186.1%) | $225.6M | |
| Energy Storage EBITDA (Segment results) | $559.8M (+351.2%) | $124.1M | |
| FY26 capital expenditures (Outlook) | $300-$350M | ~$500M prior outlook |
The strongest operating signal is pricing, not volume. Energy Storage realized prices nearly doubled to $20.02/kg LCE, lifting segment EBITDA to $560 million, but sales volume fell 19% year over year. That means the quarter confirms Albemarle’s earnings sensitivity to lithium prices more than it proves broad-based volume expansion.
The capex reduction improves financial flexibility but also signals selectivity. Cutting full-year capital spending to $300-$350 million from approximately $500 million should support cash generation and fits the company’s debt-reduction strategy. However, the filing attributes part of the reduction to resequencing early-stage projects, so it is better read as disciplined capital allocation than as evidence that growth investment is accelerating.
The near-term setup is less clean than the headline quarter. Albemarle expects fourth-quarter sales and adjusted EBITDA to decline sequentially as lithium prices fall and higher-cost spodumene inventory pressures margins. The quarter therefore advances the recovery story, but it does not remove the company’s dependence on volatile lithium pricing or eliminate execution issues around the delayed Talison CGP3 ramp. 〔0〕
Bottom line: Albemarle delivered a narrow earnings beat and strengthened cash discipline, modestly improving an already improving lithium-recovery story. The signal is positive, but the next quarter’s lower pricing and margin pressure keep this from being a major change in the business outlook.
Q4 results and lithium pricing update
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!